Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
China Journal of Chinese Materia Medica ; (24): 481-484, 2010.
Article in Chinese | WPRIM | ID: wpr-280992

ABSTRACT

<p><b>OBJECTIVE</b>To evaluate the protective effects of siwuheji on cisplatin-induced ovarian impairing and explore its possible mechanisms in mice.</p><p><b>METHOD</b>The mice received cisplatin ip (7 mg kg(-1)) for 7 days, while fed with siwuheji for 14 days. The changes of estrous cycle, ovary and uterus coefficient, levels of estrogen in serum and morphology of ovary were recorded.</p><p><b>RESULT</b>From the third day of cisplatin injection, the estrous cycle of the model group stagnated in interphase. On the thirteenth day, part of the mice fed with siquheji started with change of estrous cycle. The ovary coefficient of the model group was less than the control group, the experimental groups were no differences compared with the control group and had significant differences with the model group. The levels of E2 and P of model group were lower than the control group, but no statistical significance. The level of E2 with high-dose Siwuheji group was higher than model group, and the level of P of the low-dose group was higher than model group, but both no statistical significances. The FSH/LH ratio of model group was significantly higher than the control group, low-dose group and medium-dose group of siwuheji resumed to normal levels, and had a significantly change compared with the model group. Ovarian biopsy of model group showed the decrease in the number of developing follicle at all levels, and increase in the number of Atresia of ovarian. There were more growing follicte in the large, medium-dose group.</p><p><b>CONCLUSION</b>Cisplatin can induce mice ovarian injury and functional decline, on the other hand, siwuheji can improve cisplatin-induced ovarian dysfunction.</p>


Subject(s)
Animals , Female , Mice , Cisplatin , Drugs, Chinese Herbal , Mice, Inbred ICR , Ovarian Diseases , Drug Therapy , Ovary , Random Allocation , Uterus
SELECTION OF CITATIONS
SEARCH DETAIL